Endometrial Cancer Market on Track for Major Expansion by 2034

Strategic Insights -

The Endometrial Cancer market is experiencing significant growth due to the increasing prevalence and awareness of the disease. Emerging therapies and novel treatment strategies are also contributing to the market's expansion. According to a recent report by DelveInsight, the Endometrial Cancer market is expected to surge, with a significant CAGR during the forecast period of 2020-2034.

Key Takeaways:

  • The Endometrial Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In June 2025, Daiichi Sankyo has reported that the first patient has been dosed in the DESTINY-Endometrial01 clinical trial, which is assessing Enhertu (trastuzumab deruxtecan) in combination with either rilvegostomig or Merck's Keytruda (pembrolizumab) as a first-line treatment for patients with HER2-expressing (IHC 3+/2+), mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.
  • In May 2025, Kaida BioPharma revealed it has signed a manufacturing partnership with Northway Biotech, Inc., a full-service biologics Contract Development and Manufacturing Organization (CDMO), to produce its lead candidate, KAD101.
  • The Endometrial Cancer market is experiencing significant growth due to the increasing prevalence and awareness of the disease.
  • Emerging therapies and novel treatment strategies are also contributing to the market's expansion.
  • According to the National Cancer Institute, approximately 3 in 100 women will be diagnosed with uterine cancer at some point in their lives.
  • 80 percent of people with uterine cancer survive for five years or longer after receiving the diagnosis.
  • Endometrial cancer comprises about 4% of all cancers in women globally.
  • In the United States, the endometrium (the lining of the uterus) is the most common cancer of the female reproductive organs.
  • As per Cancer Research UK, there are around 9,700 new uterine cancer cases in the UK every year, that is 27 every day (2016-2018).
  • Among females in the UK, uterine cancer is the 4th most common cancer, with around 9,700 new cases in 2017.
  • According to the study by Aoki et al. (2020), about 380 000 new cases of endometrial cancer occur every year in the world, and about 89,000 deaths are confirmed annually.

Statistics:

  • The Endometrial Cancer market size is expected to reach $X billion by 2034.
  • The market is expected to grow at a CAGR of X% during the forecast period of 2020-2034.
  • The number of new cases of endometrial cancer is expected to increase by X% by 2034.
  • The mortality rate for endometrial cancer is expected to decrease by X% by 2034.
  • The market share of emerging therapies is expected to reach X% by 2034.

Sources:

  • DelveInsight's "Endometrial Cancer Market Insights, Epidemiology, and Market Forecast-2034"
  • National Cancer Institute
  • Cancer Research UK
  • Aoki et al. (2020)